USRE35752E - Use of hydriodic acid as an aphrodisiac - Google Patents
Use of hydriodic acid as an aphrodisiac Download PDFInfo
- Publication number
- USRE35752E USRE35752E US08/591,352 US59135296A USRE35752E US RE35752 E USRE35752 E US RE35752E US 59135296 A US59135296 A US 59135296A US RE35752 E USRE35752 E US RE35752E
- Authority
- US
- United States
- Prior art keywords
- hydriodic acid
- hydriodic
- aphrodisiac
- syrup
- adult human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 title claims abstract description 24
- 230000002509 aphrodisiac effect Effects 0.000 title claims abstract description 10
- 239000003048 aphrodisiac agent Substances 0.000 title claims abstract description 8
- 230000035946 sexual desire Effects 0.000 claims abstract description 6
- 239000007864 aqueous solution Substances 0.000 claims abstract description 5
- 239000006188 syrup Substances 0.000 claims description 8
- 235000020357 syrup Nutrition 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- 239000008121 dextrose Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims 5
- 239000000243 solution Substances 0.000 description 8
- 239000008213 purified water Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229910000043 hydrogen iodide Inorganic materials 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/18—Iodine; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Luminescent Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Materials For Photolithography (AREA)
- Photoreceptors In Electrophotography (AREA)
- Treatments Of Macromolecular Shaped Articles (AREA)
- Organic Insulating Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
This invention relates to the use of hydriodic acid in an aqueous solution as an aphrodisiac to heighten sexual desire.
Description
From the dawn of recorded history many substances have been used for the purpose of sexual enhancement. Some of these have known success and their reputations have been passed down through the millennia. Even though none of these substances have survived the rigors of scientific scrutiny the pursuit for an aphrodisiac continues. As long as humans place value on optimal sexual functioning, there will be a demand for sex-enhancing drugs.
This invention relates to the use of hydriodic acid in an aqueous solution as an aphrodisiac to heighten sexual desire.
This invention is based upon the discovery that an aqueous solution of hydriodic acid (hydriodic solution) can heighten sexual desire and, as such, can be used as an aphrodisiac.
Hydriodic acid is also known as anhydrous hydriodic acid, hydrogen iodide, hydrogen monoiodide or hydriodic. At normal temperature, hydriodic acid is a colorless and nonflammable gas. See The Merck Index, Merck & Co., Inc. (Tenth Edition 1983).
The hydriodic acid solution of the present invention consists of hydriodic acid in purified water and dextrose.
It has now been discovered that an aqueous solution of hydriodic acid has aphrodisiac activity as confirmed through its use by a female human. After the oral administration of the hydriodic acid solution, an aphrodisiac effect was experienced by said female.
The term "aphrodisiac" or "heightened sexual desire", for purposes of the present invention, refers to the following physical manifestations of ingesting the hydriodic solution, increased vaginal secretion, clitoral swelling, nipple erection, contraction of vaginal musculature and a general tingling sensation.
The invention will be further illustrated by the following non-limiting Exemplification:
Hydriodic acid solution was purchased from Eli Lilly and Company, of Indianapolis, Ind., referred to as hydriodic acid syrup. The hydriodic acid syrup is prepared by mixing 140 ml of hydriodic acid with 550 ml of purified water and dissolving 450 g of dextrose into the mixture.
The solution was orally administered to a female human 52 years age, weighing 165 lb pounds. About 0.5-3 teaspoons of the hydriodic syrup was placed into 8 ounces tap water and then ingested. An aphrodisiac effect, as defined above, was experienced within approximately 24 hours.
It is understood that higher or lower amounts and concentrations of the hydriodic solution would be used for heavier or lighter subjects as in the purview of one skilled in the art.
It should be, as well, understood that other types of administration of the hydriodic solution may be used, such as topical administration.
Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims:
Claims (4)
1. A method of heightening sexual desire of an adult human female comprising administering to an adult human female in need of said treatment, an effective amount of hydriodic acid syrup, comprising hydriodic acid, water and dextrose.
2. A method of claim 1 wherein the hydriodic acid syrup comprises 140 ml of hydriodic acid, 550 ml of water and 450 g of dextrose.
3. A method of claim 2 wherein the effective amount of hydriodic acid syrup is approximately 0.5-3 teaspoons of hydriodic acid syrup.
4. A method of claim 3 wherein the effective amount of hydriodic syrup is added into approximately 8 oz. of water before administration. .Iadd.5. A method of treatment to heighten sexual desire of an adult human female comprising administering to an adult human female in need of said treatment, an effective aphrodisiac amount of an aqueous solution of hydriodic acid. .Iaddend.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/591,352 USRE35752E (en) | 1992-04-02 | 1996-01-25 | Use of hydriodic acid as an aphrodisiac |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/862,454 US5281423A (en) | 1992-04-02 | 1992-04-02 | Use of hydriodic acid as an aphrodisiac |
| US08/591,352 USRE35752E (en) | 1992-04-02 | 1996-01-25 | Use of hydriodic acid as an aphrodisiac |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US07/862,454 Reissue US5281423A (en) | 1992-04-02 | 1992-04-02 | Use of hydriodic acid as an aphrodisiac |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| USRE35752E true USRE35752E (en) | 1998-03-24 |
Family
ID=25338522
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US07/862,454 Ceased US5281423A (en) | 1992-04-02 | 1992-04-02 | Use of hydriodic acid as an aphrodisiac |
| US08/170,151 Ceased US5470588A (en) | 1992-04-02 | 1993-12-20 | Method of increasing vaginal lubrication |
| US08/591,352 Expired - Lifetime USRE35752E (en) | 1992-04-02 | 1996-01-25 | Use of hydriodic acid as an aphrodisiac |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US07/862,454 Ceased US5281423A (en) | 1992-04-02 | 1992-04-02 | Use of hydriodic acid as an aphrodisiac |
| US08/170,151 Ceased US5470588A (en) | 1992-04-02 | 1993-12-20 | Method of increasing vaginal lubrication |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US5281423A (en) |
| EP (1) | EP0633723B1 (en) |
| JP (1) | JPH07505635A (en) |
| KR (1) | KR950700685A (en) |
| CN (1) | CN1055620C (en) |
| AT (1) | ATE184155T1 (en) |
| AU (1) | AU666196B2 (en) |
| CA (1) | CA2133563C (en) |
| DE (1) | DE69326331T2 (en) |
| DK (1) | DK0633723T3 (en) |
| ES (1) | ES2138621T3 (en) |
| WO (1) | WO1993019601A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020058072A1 (en) * | 2000-10-27 | 2002-05-16 | Susann Reilly | Use of iodide salt as an aphrodisiac |
| WO2002062355A2 (en) * | 2001-02-07 | 2002-08-15 | Rainburst, Llc | Hydriodic acid and iodide salts for treatment of male impotence |
| US20040224019A1 (en) * | 2004-03-03 | 2004-11-11 | Adi Shefer | Oral controlled release system for targeted drug delivery into the cell and its nucleus for gene therapy, DNA vaccination, and administration of gene based drugs |
| US20130209582A1 (en) * | 2010-09-27 | 2013-08-15 | Kazuyoshi Sato | Hydrogen iodide-containing health food and hydrogen iodide-containing drug, and method for producing same |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5783254A (en) * | 1980-11-12 | 1982-05-25 | Nippon Nousan Kogyo Kk | Feed for animal |
| US4670256A (en) * | 1985-09-23 | 1987-06-02 | V. Valhalla Corp. | Vaginal conditioning for sexual activity |
| RO94261A2 (en) * | 1986-01-03 | 1988-04-30 | Intreprinderea De Medicamente"Terapia",Ro | MEDICAL PRODUCT FOR SEXUAL DYNAMIC DISORDERS |
-
1992
- 1992-04-02 US US07/862,454 patent/US5281423A/en not_active Ceased
-
1993
- 1993-03-31 AU AU40248/93A patent/AU666196B2/en not_active Expired
- 1993-03-31 JP JP5517674A patent/JPH07505635A/en not_active Ceased
- 1993-03-31 WO PCT/US1993/003036 patent/WO1993019601A1/en not_active Ceased
- 1993-03-31 AT AT93909462T patent/ATE184155T1/en not_active IP Right Cessation
- 1993-03-31 CA CA002133563A patent/CA2133563C/en not_active Expired - Lifetime
- 1993-03-31 ES ES93909462T patent/ES2138621T3/en not_active Expired - Lifetime
- 1993-03-31 DK DK93909462T patent/DK0633723T3/en active
- 1993-03-31 EP EP93909462A patent/EP0633723B1/en not_active Expired - Lifetime
- 1993-03-31 DE DE69326331T patent/DE69326331T2/en not_active Expired - Lifetime
- 1993-04-02 CN CN93104577A patent/CN1055620C/en not_active Expired - Lifetime
- 1993-12-20 US US08/170,151 patent/US5470588A/en not_active Ceased
-
1994
- 1994-10-01 KR KR1019940703499A patent/KR950700685A/en not_active Withdrawn
-
1996
- 1996-01-25 US US08/591,352 patent/USRE35752E/en not_active Expired - Lifetime
Non-Patent Citations (8)
| Title |
|---|
| Buffum, Journal of Psychoactive Drugs, 14(1 2):5 44 Jan. Jun. 1982. * |
| Buffum, Journal of Psychoactive Drugs, 14(1-2):5-44 Jan.-Jun. 1982. |
| McEvoy et al; AHFS, Drug information pp. 1398 1399 (1987). * |
| McEvoy et al; AHFS, Drug information pp. 1398-1399 (1987). |
| The Merck Index, Tenth Edition, 692, 696 697, (1983). * |
| The Merck Index, Tenth Edition, 692, 696-697, (1983). |
| Waddell and Ibach, Indian J. Pharm. Sci., 51(3):79 82 (1989). * |
| Waddell and Ibach, Indian J. Pharm. Sci., 51(3):79-82 (1989). |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1081615A (en) | 1994-02-09 |
| JPH07505635A (en) | 1995-06-22 |
| EP0633723A1 (en) | 1995-01-18 |
| CA2133563A1 (en) | 1993-10-14 |
| WO1993019601A1 (en) | 1993-10-14 |
| EP0633723A4 (en) | 1995-03-01 |
| DE69326331T2 (en) | 2000-05-25 |
| EP0633723B1 (en) | 1999-09-08 |
| ATE184155T1 (en) | 1999-09-15 |
| AU666196B2 (en) | 1996-02-01 |
| US5470588A (en) | 1995-11-28 |
| KR950700685A (en) | 1995-02-20 |
| DE69326331D1 (en) | 1999-10-14 |
| AU4024893A (en) | 1993-11-08 |
| ES2138621T3 (en) | 2000-01-16 |
| US5281423A (en) | 1994-01-25 |
| DK0633723T3 (en) | 2000-03-27 |
| CN1055620C (en) | 2000-08-23 |
| CA2133563C (en) | 2004-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| McDermott et al. | Radioiodine-induced thyroid storm: case report and literature review | |
| Radó | Water intoxication during carbamazepine treatment | |
| SUN et al. | Optimal effective dose of anticholinergic drug in peptic ulcer therapy | |
| CARAVATI et al. | Salicylate toxicity: the probable mechanism of its action | |
| Crispell et al. | A cortisone-resistant abnormality in the diuretic response to ingested water in primary myxedema | |
| USRE35752E (en) | Use of hydriodic acid as an aphrodisiac | |
| Pierach et al. | Hematin therapy in porphyric attacks | |
| Derow et al. | Oral administration of mercupurin tablets in ambulatory patients with chronic congestive heart failure | |
| Ivey et al. | Effect of intravenous salicylates on the gastric mucosal barrier in man | |
| Minto et al. | “Temposil” a new drug in the treatment of alcoholism | |
| Reveno et al. | Observations on the use of antithyroid drugs | |
| WO1999016432A1 (en) | A drug for treating diabetic nephrosis | |
| AU672149B2 (en) | Method of increasing vaginal lubrication | |
| Levrat et al. | Aspirin, gastrointestinal bleeding, and peptic ulcer | |
| Leon et al. | Absence of high anion gap metabolic acidosis in severe ethylene glycol poisoning: a potential effect of simultaneous lithium carbonate ingestion | |
| Brown Jr et al. | Observations on the metabolic and antiarthritic effects of ACTH and cortisone in diabetics | |
| LINDSAY et al. | Cutaneous reactions due to sulfamethoxypyridazine | |
| US20030108621A1 (en) | Use of iodide salt as an aphrodisiac | |
| Platts | Hydrochlorothiazide, a new oral diuretic | |
| Mathew | Prophylactic pharmacotherapy of cluster headache | |
| Danowski | Diabetes mellitus and obesity: phenformin hydrochloride as a research tool | |
| Heikinheimo | Severe prolonged hypoglycemia following tolbutamide and carbutamide treatment | |
| SU388751A1 (en) | MEANS FOR THE TREATMENT OF FREE-DRUG USE OF THE OPIUM-MORPHIN GROUP | |
| Benyo et al. | Vacor Intoxication—Chemical Diabetes Extraordinary | |
| Boles et al. | The Neuroleptic Malignant Syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
| FPAY | Fee payment |
Year of fee payment: 8 |
|
| FPAY | Fee payment |
Year of fee payment: 12 |